HONG KONG – Following an approval in India, a U.S. biosimilars maker has partnered with its investor in China to expand its presence in emerging markets.
HONG KONG - For the first time, Chinese scientists have identified the molecular mechanism underlying the anorexogenic effects of a safe and effective herbal dietary supplement that is widely used for weight control, providing a promising target for the development of novel obesity drugs.
Breaking news often is the start of something bigger for drug developers and companies in the surrounding orbit. Starting with today's edition, BioWorld will include direct links to Thomson Reuters Cortellis for companies and drugs mentioned in lead articles.
SHANGHAI – Huya Bioscience International, with offices in San Diego, Tokyo and eight more across China, has set up its first China joint venture (JV) with the Tianjin Institute of Pharmaceutical Research (TIPR). The new entity is seeking to develop innovative therapeutics as well medical devices for China and global markets.
BEIJING – Two Chinese biotech companies are forming an alliance to bring a safer and more effective novel treatment for colorectal, breast and ovarian cancer patients in China.
HONG KONG - Researchers from the Chinese University of Hong Kong (CUHK) have identified a small-molecule compound that dramatically inhibited tumor growth in a mouse model of hepatocellular carcinoma (HCC), representing a promising lead candidate for further investigation as an urgently needed new class of HCC therapy.
HONG KONG – China is gradually moving toward a new medicine distribution system where pharmacies and external retailers take over sales of prescription drugs from hospitals. The gradual change could ultimately eliminate "commissions" for doctors and hospitals.
SHANGHAI – BGI, a powerhouse gene sequencing organization based in China, and the Vancouver Prostate Centre agreed to formalize their relationship by establishing a joint translational cancer research laboratory in Vancouver, British Columbia. They will use genome research to develop new biomarkers and cancer therapies, initially focusing on drug-resistant forms of bladder, kidney and prostate cancers.
HONG KONG - Treatment with cholesterol-lowering statins has been shown to induce partial recovery of bone growth in mouse models of dwarfism, suggesting those agents could be useful for the medical treatment of infants and children with growth disorders such as achondroplasia and thanatophoric dysplasia.
RSS